Capricor Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $24.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Capricor Therapeutics’ promising developments and strategic initiatives. The initiation of the Phase 1 clinical trial for the StealthX exosome-based vaccine marks a significant step, particularly with its initial focus on SARS-CoV-2 and potential expansion into other therapeutic areas. This trial, supported by the National Institute of Allergy and Infectious Diseases, showcases promising preclinical data that suggest the StealthX platform’s capability to deliver viral proteins effectively, which could lead to new revenue streams and partnerships if successful.
Moreover, Capricor’s recent engagement with the FDA regarding the Deramiocel program for Duchenne Muscular Dystrophy (DMD) adds another layer of potential value. Despite the unexpected Complete Response Letter (CRL) from the FDA, the company’s ongoing discussions and plans to address FDA concerns demonstrate a proactive approach. The anticipation of feedback from the recent Type A meeting with the FDA could provide further clarity and direction, potentially enhancing Capricor’s strategic positioning in the market.
According to TipRanks, Pantginis is an analyst with an average return of -8.8% and a 39.20% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, aTyr Pharma, and Krystal Biotech.
In another report released on August 13, Maxim Group also reiterated a Buy rating on the stock with a $25.00 price target.